Short answer
CAPRICOR THERAPEUTICS, INC. (CAPR) filed an 8-K current report with the SEC on May 7, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Capricor filed a New Jersey lawsuit seeking equitable relief and a preliminary injunction.
CAPRICOR THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Capricor filed a New Jersey lawsuit seeking equitable relief and a preliminary injunction
- Litigation introduces potential operational and strategic uncertainty for investors
- Press release and Complaint filed as Exhibits 99.1 and 99.2 for substantive allegations and requested remedies
Item 8.01 · Other Events
- Capricor sued Nippon Shinyaku and NS Pharma over Deramiocel distribution and alleged pricing flaws
- Requested rescission of the U.S. Distribution Agreement, potentially restoring direct or alternative distribution rights
- Alleged inadequate commercial-launch preparation and material contractual breaches by NS
- Preliminary injunction request creates near-term uncertainty around Deramiocel’s U.S. commercialization
- Litigation outcome could materially affect launch timing, distribution economics, and future revenue realization
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CAPRICOR THERAPEUTICS, INC. 8-K filings
Get the next CAPR 8-K as it lands
Follow CAPR for push alerts, or ask the research agent what this filing means.